Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts
Portfolio Pulse from Benzinga Insights
Analyst ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) show varied opinions, with recent updates indicating a mix of bullish and neutral stances. The average 12-month price target has increased to $94.33, up 22.19% from $77.20, with actions ranging from maintaining to raising ratings and price targets by analysts from firms like Cantor Fitzgerald, JP Morgan, Canaccord Genuity, Wedbush, and Baird. Ultragenyx, a biopharmaceutical company focusing on rare diseases, has shown a revenue growth of 23.27% and a net margin of -96.7%, with a below-average market capitalization and ROE of -80.22%.
April 05, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx Pharmaceutical has received mixed analyst ratings, with a notable increase in the average 12-month price target to $94.33, indicating a positive outlook from some analysts despite varied opinions.
The increase in the average price target suggests a positive sentiment among some analysts, which could lead to short-term bullish behavior in the stock price. However, the mix of ratings indicates that investor reactions may vary, potentially leading to volatility.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100